Chronic inflammatory demyelinating polyradiculoneuropathy
Also known as: CIDP, Chronic inflammatory demyelinating polyneuropathy, Chronic immune-mediated demyelinating polyradiculoneuropathy
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated peripheral neuropathy characterised by progressive or relapsing weakness, sensory disturbance, and reduced reflexes. Diagnosis and disease-modifying therapy necessitate neurological assessment; atypical presentations or treatment-refractory cases warrant reconsideration of toxic and paraneoplastic mimics. the cited evidence comprises three case reports and one retrospective treatment cohort, not acupuncture or herbal trials; it cannot establish TCM efficacy, remyelination, or prevention of relapse. Practitioner-delivered TCM is strictly adjunctive, symptom-oriented care alongside prescribed medical interventions and rehabilitation. Traditional patterns represent interpretive frameworks rather than diagnostic subtypes of CIDP and must never delay investigation or specialist treatment.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere to activity pacing as directed by physiotherapy, incorporating rest intervals to avoid exacerbating muscular weakness.
- •Mitigate falls risk by maintaining clear walkways, ensuring adequate lighting, and utilising professionally fitted mobility aids.
- •Perform daily integumentary inspections of insensate extremities for trauma; ensure footwear is appropriately fitted and avoid thermal applications to areas with sensory deficits.
- •Maintain a systematic log of walking ability, hand tasks, falls, sensory discomfort, and treatment changes for clinical review by the neurology team.
Cautions & Contraindications
- •Do not use TCM as a reason to stop or taper prescribed immunotherapy. Relapses during corticosteroid tapering occurred in the supplied case; medication changes belong with the treating specialist.[]
- •Avoid unidentified or untraceable herbal products, including topical preparations. The supplied report links unidentified topical herbal exposure with arsenic-associated neuropathy; product quality and exposure history require explicit review.[]
- •Do not continue adjunctive care as the sole response to neurological deterioration or unexplained weight loss. Reopen the differential diagnosis promptly; toxic and paraneoplastic neuropathies can be mistaken for CIDP.[,]
When to reassess or seek care again
Record baseline sensory discomfort and fatigue on 0–10 scales, sleep disruption, falls and one safe functional task agreed with rehabilitation staff. Review tolerability after every session and benefit within 2–4 weeks. Coordinate any available I-RODS or INCAT assessments with neurology; these measures appear in the supplied retrospective cohort but do not establish TCM efficacy. Stop or revise adjunctive care if there is no meaningful benefit by four weeks. New objective weakness, reduced walking ability or new cranial nerve symptoms requires prompt neurological reassessment rather than waiting for the scheduled review.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Frontiers in immunology · 2026
- Medicine · 2026
- Frontiers in toxicology · 2026
- Annals of clinical and translational neurology · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
